Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised ...
BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...
Low-dose colchicine not only lowers the risk of ischemic CV events post-MI, it also can do so cost-effectively, according to the latest numbers from COLCOT. This is true from the perspective of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results